AIM ImmunoTech highlights Ampligen pancreatic cancer strategy
AIM ImmunoTech said its Ampligen pancreatic cancer strategy is drawing growing attention as DURIPANC advances toward topline data.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.